Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118723 · ClinicalTrials.gov registry record
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A clinical trial of Glioblastoma and High Grade Glioma, sponsored by Jasper Gerritsen.
- Recruiting
- Registry status
- 784
- Enrollment target
- 8
- Study locations
NCT06118723 is a study of Glioblastoma and High Grade Glioma that is actively recruiting participants, run by Jasper Gerritsen. The registered enrollment target is 784 participants, above the 105-participant average among 199 other Glioblastoma trials with a reported enrollment target (647% higher). The trial reports 8 study locations across 6 states.
The verdict
NCT06118723, a study of Glioblastoma and High Grade Glioma, is actively recruiting participants, sponsored by Jasper Gerritsen.
- RECRUITING
- Registry status
- 784 participants
- Enrollment target
- 8
- Study locations
Study Summary
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). Therefore, this study evaluates the efficacy and safety of SMR with and without mapping techniques in HGG patients in terms of survival, functional, neurological, cognitive, and quality of life outcomes. Furthermore, it evaluates which patients benefit the most from SMR, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be operated with supramaximal resection or maximal resection at a 1:3 ratio. Primary endpoints are: 1) overall survival and 2) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months postoperatively. Secondary endpoints are 1) residual CE and NCE tumor volume on postoperative T1-contrast and FLAIR MRI scans 2) progression-free survival; 3) onco-functional outcome, and 4) quality of life at 6 weeks, 3 months, and 6 months postoperatively. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).
Conditions Studied
Interventions
- PROCEDURE Supramaximal resection
- PROCEDURE Maximal safe resection
Study Locations (8)
Other
- University Hospitals Leuven - Leuven
- Inselspital Universitätsspital Bern - Bern
South Holland
- Erasmus Medical Center - Rotterdam
- Haaglanden Medical Centre - The Hague
California
- University of California, San Francisco (UCSF) - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Baden-Wurttemberg
- Universitätsklinikum Heidelberg - Heidelberg
Bavaria
- Technical University Munich - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2028-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118723
The ClinicalTrials.gov registry entry for NCT06118723 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 784 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 105-participant average among 199 other Glioblastoma trials with a reported enrollment target (647% higher). The listed sponsor is Jasper Gerritsen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Supramaximal resection is the first listed.
NCT06118723 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Other, South Holland, California.
Frequently Asked Questions
What is clinical trial NCT06118723 about?
NCT06118723 is a clinical study titled "The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)". A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). Th...
What is the current status of trial NCT06118723?
This trial is currently recruiting. The enrollment target is 784 participants. The study started on 2022-01-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06118723 study?
This clinical trial studies the following conditions: Glioblastoma, High Grade Glioma, Glioblastoma, IDH-wildtype, Brain Neoplasms, Glioblastoma Multiforme, Adult.
What interventions are being tested in trial NCT06118723?
The interventions under investigation include: Supramaximal resection (PROCEDURE), Maximal safe resection (PROCEDURE).
Who is sponsoring clinical trial NCT06118723?
This trial is sponsored by Jasper Gerritsen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118723 being conducted?
This trial has 8 study locations across California, Massachusetts, Baden-Wurttemberg, Bavaria, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.